补体异常与肝硬化关系研究进展*

doi:10.3969/j.issn.1672-5069.2014.06.030

Abstract

Zhou Xinren, Wang Fang. Abnormal complement balance in patients with liver cirrhosis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(6): 669-672.

[1] 邱国华,高媛娇,谢尧,等.肝病患者血清补体C3 检测的临床意义. 中华实验和临床感染病杂志（电子版）,2012,6（2）：125-128.
[2] Strey CW,Markiewski M,Mastellos D,et al. The proinflammatory mediators C3a and C5a are essential for liver regeneration. J Exp Med,2003,198（6）:913-923.
[3] 钱金娟,裴豪,邓历,等.乙型肝炎患者血清免疫球蛋白、补体的检测及临床意义.中国实验诊断学,2009,13（6）：836-837.
[4] 韦丽霞,唐任光,杨柳,等.免疫球蛋白及补体检测在肝炎诊断中的意义.右江民族医学院学报,2006,28（2）：266.
[5] 张雪华,李仲平.血清补体C3、C4测定在病毒性肝炎患者中的临床意义.中国社区医师,2012,10（14）：258-259.
[6] 杨晋辉,李祥金.乙型病毒性肝炎患者血清补体C3、补体C4 的临床意义.临床肝胆病杂志,2007,23（5）：355.
[7] 尧颖,杨晋辉,徐智媛,等.原发性胆汁性肝硬化血清免疫学检测的临床意义.胃肠病学和肝病学杂志,2007,16（5）：417-419.
[8] 严莉莉. 原发性胆汁性肝硬化免疫发病机制的研究探析.中外医学研究,2013,5（14）：137-138.
[9] Bykov I,Junnikkala S,Pekna M,et al. Complement C3 contributes to ethanol-induced liver steatosis in mice. Ann Med,2006, 38（4）:280-286.
[10] Pritchard MT,McMullen MR,Nagy LE,et al. Differential contributions of C3,C5 and decay-accelerating factor to ethanol-induced fatty liver in mice. Gastroenterology,2007,132（3）:1117-1126.
[11] Faraj M,Cianflone K. Differential regulation of fatty acid trapping in mouse adipose tissue and muscle by ASP. Am J Physiol Endocrinol Metab,2004,287（1）:150-159.
[12] Bykov I,Jauhiainen M,Olkkonen VM,et al. Hepatic gene expression and lipid parameters in complement C3（-/-） mice that do not develop ethanol-induced steatosis. J Hepatol, 2007,46（5）:907-914.
[13] Cianflone K,Xia Z. Critcal review of aclation-stimulating protein physioloy in humans and rodents. Biochim Biophys Acta, 2003,1609（2）:127-143.
[14] Nagy LE,Cohen JI,Roychowdhury S,et al. Complement and alcoholic liver disease:role of C1q in the pathogenesis of ethanol-induced liver injury in mice. Gastroenterology,2010,139（2）:664-674.
[15] 佘为民. 乙型肝炎病毒变异与重症肝炎关系探讨. 肝脏,2004,9（2）：121-122.
[16] Antúnez C,Boada M,López-Arrieta J,et al.Genetic association of complement receptor 1 polymorphism rs3818361 in Alzheimer's disease.Alzheimers Dement,2011,7（4）:124-129.
[17] Brekke OL,Hellerud BC,Christiansen D. Neisseria meningitidis and Escherichia coli are protected from leukocyte phagocytosis by binding to erythrocyte complement receptor 1 in human blood.Mol Immunol,2011,48（15-16）:2159-2169.
[18] Odera M,Otieno W,Adhiambo C,et al. Dual role of erythrocyte complement receptor type 1 in immune complex-mediated macrophage stimulation:implications for the pathogenesis of Plasmodium falcipa-rum malaria.Clin Exp Immunol,2011, 166（2）: 201-207.
[19] Luan NM,Teramura Y,Iwata H. Layer-by-layer co-immobilization of soluble complement receptor 1 and heparin on islets. Biomaterials,2011,32（27）:6487-6492.
[20] 郑卫东,庞君丽,王海滨,等.重型肝炎患者红细胞补体型受体基因多态性与血清可溶性补体型受体含量的变化及意义研究.中华临床医师杂志（电子版）,2012,6（11）：3006-3009.
[21] 董格峰,刘典勇,王海滨,等.重型肝炎患者血清可溶性补体受体Ⅰ型的变化及临床意义.中华肝脏病杂志,2004,2（12）：108-109.
[22] 李文华,刘玉凤,郭瑛,等.重型肝炎T细胞亚群、免疫球蛋白及补体C3的临床观察.传染病信息,2007,20（5）：306-308.
[23] 柳黎.血清肝纤维化指标在慢性肝病诊断中的应用.当代医学杂志,2010,12（31）：82.
[24] 张雪华,李仲平.血清补体C3 、C4测定在病毒性肝炎患者中的临床意义. 中国社区医师,2012,10（12）：258-259.
[25] 邱国华,高媛娇,谢尧,等.肝病患者血清补体C3 检测的临床意义. 中华实验和临床感染病杂志（电子版）,2012,6（2）：125-128.
[26] Qin X,Gao B.The complement system in liver diseases. Cell Mol Immunol,2006,3（5）:333-340.
[27] 赵华江. 肝硬化患者红细胞CR1粘附活性与肝功能损伤的关系.放射免疫学杂志,2005,18（6）：496-497.
[28] 张建春,翁锡定,陈孙云,等.乙型肝炎患者外周血T淋巴细胞亚群的变化.实用肝脏病杂志,2013,16（4）：356-357.
[29] Wang SD,Chen LP. Co-signaling molecules of the B7-CD28 family in positive and negative regulation of T lymphocyte response. Microbes Infect,2004,6（8）:759-766.
[30] 严国度,戚传平,奚剑波,等. 门静脉高压症患者外周血CD88/CD28的表达. 中国医学工程,2010,9（3）：17-19.
[31] 俞幼林. 肝硬化脾功能亢进患者脾切除术后免疫功能变化.全科医学临床与教育,2010,7（4）：400-401.
[32] 莫锋利. 肝肾综合征患者血清补体C3、C4测定的临床意义.中国临床实用医学,2009,1（2）：328-330.
[33] 郑敬民,尹广,姚根宏,等. 肾病患者肾组织补体活化与肥大细胞浸润的关系研究.医学研究生学报,2012,10：1040-1044.
[34] 周杰,李德昌,丘可清,等.肝硬化自发性细菌性腹膜炎患者血清补体C3、B 因子水平研究. 临床和实验医学杂志,2008,7（9）：1-2.
[35] 索标,白龙,曹霞,等. 联合检测腹水总蛋白、补体C3、IL-6及TNF-α对自发性细菌性腹膜炎的诊断价值. 临床消化病杂志,2001,13（1）：33-34.
[36] Kanmura S,Uto H,Sato Y,et al.The complement component C3a fragment is a potential biomarker for hepatitis C virus-related hepatocellular carcinoma.J Gastroenterol,2010,45（4）:459-467.
[37] 林治华,万瑾,谢伟,等.补体系统与肿瘤免疫.重庆理工大学学报（自然科学版）,2010,24（5）：33-36.
[38] Macor P,Tedesco F. Complement as effector system in cancer immunotherapy. Immunol Lett,2007,111（1）:6-13.
[39] Kim AH,Dimitriou ID,Holland MC,et al. Complement C5a receptor is essential for the optimal generation of antiviral CD8 Tcell responses. J Immunol,2004,173（4）：2524-2529.
[40] 张秀琴,潘宝龙,雷家林. 肝癌患者血清补体检测的临床意义.现代诊断与治疗,2007,18（2）：75-77.
[41] 魏新亮,陈霞,王亮,等.肝癌患者不同Child-Pugh 分级时补体C3 的表达意义. 中国误诊学杂志,2011,11（1）：37-38.

Abnormal complement balance in patients with liver cirrhosis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhuang Ying, Lin Zhihui.. Clinical manifestations and diagnosis of portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 765-767.
[2]	Yang Caiyong, Chen Na, Li Kui, et al.. Clinical significance of peripheral blood Treg and Th17 cells in patients with chronic hepatitis C and hepatitis C-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 868-871.
[3]	Zhu Yage, Liu Jinfeng.. Therapeutic efficacy of adenosine methionine and glycyrrhizin combination in treatment of patients with alcoholic cirrhosis and its effect on serum BGP levels [J]. Journal of Practical Hepatology, 2019, 22(6): 872-875.
[4]	Wu Dan Ma Xiangying.. Insulin resistance,carotid atherosclerosis and left ventricular function in patients with NAFLD-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 876-879.
[5]	Chen Meimei, Duan Xiaoyan, Cao Haixia, et al.. Improvement of clinical symptoms and serum hepatic fibrosis markers in patients with primary biliary cirrhosis by compound Biejiaruangan tablets [J]. Journal of Practical Hepatology, 2019, 22(6): 880-883.
[6]	Liu Li, Yang Lie, Chen Haiyang, et al.. Changes of hemodynamics after splenectomy combined with pericardial devascularization in patients with cirrhotic portal hypertention complicated by splenic artery steal syndrome [J]. Journal of Practical Hepatology, 2019, 22(6): 884-887.
[7]	He Zhi’an, Yu Liping, Lai Jiangqiong, et al.. Evaluation of varices bleeding and portal vein thrombosis by ARFI in patients with cirrhosis and esophagogastric varices [J]. Journal of Practical Hepatology, 2019, 22(6): 888-891.
[8]	Du Keye, Yang Dongliang, Liu Jia. Regulatory T cells in hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 613-616.
[9]	Wang Yueyuan, Wang Yan, Zhang Dandan. Short-term efficacy of terlipressin and octreotide combination in treatment of cirrhotic patients complicated by hepatorenal syndrome [J]. Journal of Practical Hepatology, 2019, 22(5): 684-687.
[10]	Zhang Mei, Shi Xiuying, Li Linjuan, et al. Hepatic expression of interferon inducible protein -10 in patients with hepatitis B liver cirrhosis and hepatogenic diabetes mellitus [J]. Journal of Practical Hepatology, 2019, 22(5): 688-691.
[11]	Dan Zhuyongji, Liu Zhilan, Lu Yanyan, et al. Efficacy of endoscopic sequential variceal 1igation plus sclerotherapy in treatment of patients with hepatitis B-induced liver cirrhosis complicated by esophageal gastric varices bleeding [J]. Journal of Practical Hepatology, 2019, 22(5): 692-695.
[12]	Huang Hanjun, Lu Fengrong, Zhang Can. Clinical value of MRI scanning based on exchange hemodynamics model in evaluating liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(5): 696-699.
[13]	Zhao Fangfang, Zhai Yongzhen, Feng Guohe. Efficacy and safety of autologous peripheral blood stem cell transplantation in patients with hepatitis B cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(5): 700-703.
[14]	Chen Shan, Zhuang Huashuai, Xing Yixi, et al. Preventive application of meropenem in patients with liver cirrhosis complicated by upper gastrointestinal bleeding [J]. Journal of Practical Hepatology, 2019, 22(5): 704-707.
[15]	Xu Qilin, Hao Shaohuan, Ran Bo. Risk factors of portal vein thrombosis after splenectomy in patients with liver cirrhosis and portal hypertension [J]. Journal of Practical Hepatology, 2019, 22(5): 708-711.